Back to News
Apr 13, 2026 12:00 PM

Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

Revolution Medicines Inc. (NASDAQ:RVMD) shares are up during Monday’s premarket session following positive topline results from its Phase 3 RASolute 302 clinical trial evaluating daraxonrasib for metastatic pancreatic cancer.

The late-stage clinical oncology company is focused on developing targeted therapies for patients with RAS-addicted cancers.

Daraxonrasib Shows Significant Survival Advantage Over Chemotherapy

In the RASolute 302 trial, daraxonrasib showed statistically significant improvements in progression-free survival and overall survival, which are critical endpoints for cancer therapies.

The stock’s movement aligns with the company’s announcement that daraxonrasib demonstrated a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy.

The company plans to submit these findings to regulatory authorities for future applications.

The company intends to present these results at the 2026 American Society of Clinical Oncology Annual Meeting, highlighting the ...